"10.1371_journal.pone.0019767","plos one","2011-05-23T00:00:00Z","Agnes Floel; Tobias Warnecke; Thomas Duning; Yvonne Lating; Jan Uhlenbrock; Armin Schneider; Gerhard Vogt; Rico Laage; Winfried Koch; Stefan Knecht; Wolf-Rüdiger Schäbitz","Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany; Cluster of Excellence NeuroCure, Charité-Universitätsmedizin Berlin, Berlin, Germany; Department of Neurology, University of Münster, Münster, Germany; SYGNIS Bioscience, Heidelberg, Germany; HAAPACS GmbH, Schriesheim, Germany; Department of Neurology, Bethel, Evangelisches Krankenhaus Bielefeld (EVKB), Bielefeld, Germany","Conceived and designed the experiments: AF AS SK RL W-RS. Performed the experiments: TW TD YL JU. Analyzed the data: GV WK. Contributed reagents/materials/analysis tools: RL TW. Wrote the paper: AF AS SK W-RS.","AS, RL, GV are employees of SYGNIS Bioscience GmbH. WK is employee of HAPAACS. This was an investigator-initiated trial, and SYGNIS Bioscience provided study material, but was not involved in trial design, study protocol generation, study conduct, or regulatory issues. AS, RL, GV and WK were involved in generating the statistical analysis plan, and conducted statistical analysis of trial outcome. AS, WRS are inventors on a number of patent applications claiming the use of G-CSF for neurological diseases including stroke. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.",NA,NA,NA,"2011","05","Agnes Floel","AF",11,TRUE,5,4,2,4,TRUE,FALSE,TRUE,1,"11",TRUE
